Anne Sophie Bargnoux
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Anne Sophie Bargnoux has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Jean-Paul Cristol
Laboratoire de Biochimie et Hormonologie, CHU Montpellier, Univ. Montpellier 1 , Montpellier
18 shared publications - Anne-Marie Dupuy
Laboratoire de Biochimie et Hormonologie, CHU Montpellier, Univ Montpellier 1, Montpellier, F-34295, cédex 5, France
15 shared publications Stéphanie Badiou
Biochemistry Laboratory, Lapeyronie Hospital, Montpellier, France
10 shared publicationsNils Kuster
4 shared publications- Pierre Delanaye
University of Liège, CHU Sart Tilman Department of Nephrology-Dialysis-Transplantation Liège
3 shared publications Stephanie Badiou
3 shared publications
Latest Publications
- 5 December 2023
- Published by Taylor & Francis in Bioanalysis
- Vol. 16 (2) , 65-74
Free Hemoglobin Determination at Patients’ Bedside to Evaluate Hemolysis
Background: The authors report the relevance of using a point of care test (Helge®) for free hemoglobin determination and concordance of the values the with Cobas® 8000 and spectrophotometer method...
- 5 December 2023
- Published by Taylor & Francis in Bioanalysis
- Vol. 16 (2) , 65-74
Free Hemoglobin Determination at Patients’ Bedside to Evaluate Hemolysis
Background: The authors report the relevance of using a point of care test (Helge®) for free hemoglobin determination and concordance of the values the with Cobas® 8000 and spectrophotometer method...
- Open Access
- 22 November 2021
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 60 (3) , 77-80
Analytical evaluation of the performances of a new procalcitonin immunoassay
Article Analytical evaluation of the performances of a new procalcitonin immunoassay was published on November 22, 2021 in the journal Clinical Chemistry and Laboratory Medicine (CCLM) (volume 0, issue 0).
- 22 November 2021
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 60 (3) , 77-80
Open AccessAnalytical evaluation of the performances of a new procalcitonin immunoassay
Article Analytical evaluation of the performances of a new procalcitonin immunoassay was published on November 22, 2021 in the journal Clinical Chemistry and Laboratory Medicine (CCLM) (volume 0, issue 0).
- 27 November 2018
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 13 (1) , 150-151
Evaluation of Point of Care Analyzer for Hemoglobin A1c
- 27 November 2018
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 13 (1) , 150-151
Evaluation of Point of Care Analyzer for Hemoglobin A1c
- Open Access
- 1 May 2018
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 33 (suppl_1) , i166
FP391LUMIPULSE W-PTH© 3RD GENERATION ASSAY: REFERENCE VALUES IN HEALTHY POPULATION AND CLASSIFICATION OF SECONDARY HYPERPARATHYROIDISM IN CKD
INTRODUCTION AND AIMS: The 3rd generation PTH assays detect the only total bioactive 1-84 fragment. Since standardization is still lacking, each new PTH assay requires to establish reference values and to assess the impact in the medical care of the mineral and bone disorders in CKD5 patients.
- 1 May 2018
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 33 (suppl_1) , i166
Open AccessFP391LUMIPULSE W-PTH© 3RD GENERATION ASSAY: REFERENCE VALUES IN HEALTHY POPULATION AND CLASSIFICATION OF SECONDARY HYPERPARATHYROIDISM IN CKD
INTRODUCTION AND AIMS: The 3rd generation PTH assays detect the only total bioactive 1-84 fragment. Since standardization is still lacking, each new PTH assay requires to establish reference values and to assess the impact in the medical care of the mineral and bone disorders in CKD5 patients.
- 1 March 2017
- Published by Elsevier in Diabetes & Metabolism
- Vol. 43 (2) , A100
L’hypertriglycéridémie, un marqueur simple et pratique pour dépister l’insulinorésistance chez le patient obèse
- 1 March 2017
- Published by Elsevier in Diabetes & Metabolism
- Vol. 43 (2) , A100
L’hypertriglycéridémie, un marqueur simple et pratique pour dépister l’insulinorésistance chez le patient obèse
- 1 December 2016
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 38 (6) , 808-812
Evaluation of the New Siemens Tacrolimus Assay on the Dimension EXL Integrated Chemistry System Analyzer: Comparison With an Ultra-Performance Liquid Chromatography–Tandem Mass Spectrometry Method
Many patients are maintained at the lower end of the tacrolimus (TAC) reference range (3-7 ng/mL), requiring the use of analytical methods displaying a very low limit of quantification for their follow-up. Therefore, the new Dimension TAC, based on affinity chrome-mediated immunoassay technology, was evaluated on the Dimension EXL Integrated Chemistry System (Siemens Healthcare Diagnostics Inc). The aims of this study were (1) to evaluate the analytical performances with special emphasis on sensibility at low levels of TAC, (2) to compare the results with an ultra-performance liquid chromatography-tandem mass spectrometry (UPLC/MS/MS) method. Analytical performance (imprecision, linearity, limit of detection, and limit of quantification) was evaluated. Comparison to UPLC/MS/MS was performed on 106 whole blood samples from 88 transplant recipients using regression analysis and Bland-Altman plot analysis. Repeatability and within-laboratory coefficients of variation were <6% at mean TAC control levels of 3.7, 11.7, and 19.2 ng/mL. Linearity was confirmed between 1.0 and 22 ng/mL. Passing-Bablok regression analysis of Siemens TAC assay in comparison with UPLC/MS/MS values displayed a slope of 1.09 and an intercept of -0.42. Using Bland-Altman analysis, the mean bias was 0.27 ng/mL with 1.96 SD limits of -2.14 and 2.67 ng/mL. The new Dimension TAC immunoassay on the EXL analyzer demonstrated reliable and reproducible performances allowing routine monitoring in transplant patients, even at TAC concentrations at the lower end of the therapeutic range.
- 1 December 2016
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 38 (6) , 808-812
Evaluation of the New Siemens Tacrolimus Assay on the Dimension EXL Integrated Chemistry System Analyzer: Comparison With an Ultra-Performance Liquid Chromatography–Tandem Mass Spectrometry Method
Many patients are maintained at the lower end of the tacrolimus (TAC) reference range (3-7 ng/mL), requiring the use of analytical methods displaying a very low limit of quantification for their follow-up. Therefore, the new Dimension TAC, based on affinity chrome-mediated immunoassay technology, was evaluated on the Dimension EXL Integrated Chemistry System (Siemens Healthcare Diagnostics Inc). The aims of this study were (1) to evaluate the analytical performances with special emphasis on sensibility at low levels of TAC, (2) to compare the results with an ultra-performance liquid chromatography-tandem mass spectrometry (UPLC/MS/MS) method. Analytical performance (imprecision, linearity, limit of detection, and limit of quantification) was evaluated. Comparison to UPLC/MS/MS was performed on 106 whole blood samples from 88 transplant recipients using regression analysis and Bland-Altman plot analysis. Repeatability and within-laboratory coefficients of variation were <6% at mean TAC control levels of 3.7, 11.7, and 19.2 ng/mL. Linearity was confirmed between 1.0 and 22 ng/mL. Passing-Bablok regression analysis of Siemens TAC assay in comparison with UPLC/MS/MS values displayed a slope of 1.09 and an intercept of -0.42. Using Bland-Altman analysis, the mean bias was 0.27 ng/mL with 1.96 SD limits of -2.14 and 2.67 ng/mL. The new Dimension TAC immunoassay on the EXL analyzer demonstrated reliable and reproducible performances allowing routine monitoring in transplant patients, even at TAC concentrations at the lower end of the therapeutic range.
- 1 January 2016
- Vol. 62 (3)
Procalcitonin, an Independent Marker of Abdominal Fat Accumulation in Obese Patients.
- 1 January 2016
- Vol. 62 (3)
Procalcitonin, an Independent Marker of Abdominal Fat Accumulation in Obese Patients.
- 1 January 2014
- Published by Elsevier in Clinica Chimica Acta
- Vol. 428, 89-95
Enzymatic creatinine assays allow estimation of glomerular filtration rate in stages 1 and 2 chronic kidney disease using CKD-EPI equation
- 1 January 2014
- Published by Elsevier in Clinica Chimica Acta
- Vol. 428, 89-95
Enzymatic creatinine assays allow estimation of glomerular filtration rate in stages 1 and 2 chronic kidney disease using CKD-EPI equation